Evidence mapPaperPMID 39026037Full record

ReviewNature reviews. Molecular cell biology2024

Regulation of and challenges in targeting NAD

Marie E Migaud, Mathias Ziegler, Joseph A Baur

Abstract readReview
In one paragraph

Review in Nature reviews. Molecular cell biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. NADPharmaceutical science advances · 2026
    Article
  5. A sustained NADBioactive materials · 2026
    Article
  6. Review
  7. Semiartificial COChemical reviews · 2026
    Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Skin Cancer Prevention and Antiaging: Role of Nicotinamide.International journal of molecular sciences · 2026
    Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Marie E MigaudMitchell Cancer Institute, Department of Pharmacology, Frederick P. Whiddon College of Medicine, University of South Alabama, Mobile, AL, USA. mmigaud@southalabama.edu.ORCID http://orcid.org/0000-0002-9626-2405
Mathias ZieglerDepartment of Biomedicine, University of Bergen, Bergen, Norway. mathias.ziegler@uib.no.ORCID http://orcid.org/0000-0001-6961-2396
Joseph A BaurDepartment of Physiology, University of Pennsylvania, Philadelphia, PA, USA. baur@pennmedicine.upenn.edu.

Funding

Targeting NAD Metabolism to Improve Glucose Homeostasis in Obesity and AgingR01DK098656 · NIDDK · UNIVERSITY OF PENNSYLVANIA · 2022 to 2025
$1.4M
Understanding the roles of cardiac NAD pools and therapeutic effects of precursor supplements in heart failureR01HL165792 · UNIVERSITY OF PENNSYLVANIA · 2025 to 2025
$635k
NHLBI NIH HHS R01 HL165792NIDDK NIH HHS R01 DK098656
6 · The paper itself

Abstract

Nicotinamide adenine dinucleotide, in its oxidized (NAD

Indexed as

NADAnimalsHumansNiacinamideNicotinamide MononucleotideOxidation-ReductionPyridinium CompoundsNADNiacinamidenicotinamide-beta-ribosideNicotinamide MononucleotidePyridinium Compounds

Identifiers

PMID39026037
PMCPMC12456757

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.